NCT06703346 is a Phase 2 clinical trial of Letetresgene autoleucel (Lete-Cel (GSK3377794)) in Neoplasms, sponsored by USWM CT, LLC.

Who is sponsoring NCT06703346?

NCT06703346 is sponsored by USWM CT, LLC.

What drugs are being tested in NCT06703346?

Interventions in NCT06703346: Letetresgene autoleucel (Lete-Cel (GSK3377794)), Cyclophosphamide, Fludarabine.

Is NCT06703346 still recruiting?

NCT06703346 is currently active, enrolled. Last updated 8 April 2026.

Last reviewed 2026-04-08 · How we verify

NCT06703346

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Study to Evaluate Safety and Antitumor Activity of Lete-Cel (GSK3377794) in HLA-A2+ Participants With NY-ESO-1 Positive Previously Treated Advanced (Metastatic or Unresectable) Synovial Sarcoma or Myxoid/Round Cell Liposarcoma

Active, enrolled Phase 2 Last updated 8 April 2026

What this trial tests

Phase 2 trial testing Letetresgene autoleucel (Lete-Cel (GSK3377794)) in Neoplasms in 87 participants. Participants enrolled and being followed up; not accepting new ones.

Timeline

31 December 2019

Primary endpoint
1 March 2024

31 July 2026

Quick facts

Lead sponsor	USWM CT, LLC
Phase	Phase 2
Status	Active, enrolled
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	87
Start date	31 December 2019
Primary completion	1 March 2024
Estimated completion	31 July 2026
Sites	38 locations across France, Italy, Netherlands, United Kingdom, Canada, United States, Spain

Drugs / interventions tested

Letetresgene autoleucel (Lete-Cel (GSK3377794)) — full drug profile →
Cyclophosphamide (cyclophosphamide) — full drug profile →
Fludarabine (FLUDARABINE) — full drug profile →

Conditions studied

Neoplasms — all drugs for Neoplasms →

Sponsor

USWM CT, LLC — full company profile →

Who can join

10 and older, any sex, with Neoplasms. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This trial will evaluate safety and efficacy of human engineered T-cell therapies, in participants with advanced tumors. This trial is a sub study of the Master study NCT03967223.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Review of Adoptive Cellular Therapies for the Treatment of Sarcoma.
Fradin JJ, Charlson JA. · · 2025 · cited 3× · PMID 40282478 · DOI 10.3390/cancers17081302

Verify or expand the search:

Other recruiting trials for Neoplasms

Currently open trials in the same condition.

NCT07438782 — First Time in Human (FTIH) Study to Investigate the Safety and Preliminary Activity of GSK5533524 Alone or in Combinatio · Phase 1 · recruiting
NCT07382817 — Phase 1 Study of JV-394 Autologous Anti-CD94 CAR T for r/r CD94+ T/NK Cell Neoplasms · Phase 1 · recruiting
NCT07277270 — A Study of GSK5764227 in Combination With Standard of Care (SoC) or Other Agents in Participants With Advanced Solid Tum · Phase 1 · recruiting
NCT07257640 — IL-5 CAR-T Cell Therapy for Refractory/Relapsed Eosinophilic Leukemia · Phase 1 · recruiting
NCT07213609 — A Study to Investigate the Safety and Preliminary Efficacy of GSK5460025 Alone or in Combination With Other Anti-cancer · Phase 1, PHASE2 · recruiting

Other USWM CT, LLC trials

Trials by the same sponsor.

NCT05642455 — SPEARHEAD-3 Pediatric Study · Phase 1, PHASE2 · recruiting
NCT05601752 — ADP-A2M4CD8 Monotherapy and in Combination With Nivolumab in HLA-A2+ Subjects With MAGE-A4 Positive Ovarian Cancer (SURP · Phase 2 · active not recruiting
NCT03967223 — Master Protocol to Assess the Safety and Antitumor Activity of Genetically Engineered T Cells in NY-ESO-1 and/or LAGE-1a · Phase 2 · active not recruiting
NCT04044859 — ADP-A2M4CD8 as Monotherapy or in Combination With Either Nivolumab or Pembrolizumab in HLA-A2+ Subjects With MAGE-A4 Pos · Phase 1 · active not recruiting
NCT04044768 — Spearhead 1 Study in Subjects With Advanced Synovial Sarcoma or Myxoid/Round Cell Liposarcoma · Phase 2 · active not recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06703346 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by USWM CT, LLC
Last refreshed: 8 April 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06703346.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing